Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bupropion is a nicotinic antagonist.

J E Slemmer1, B R Martin, M I Damaj

  • 1Department of Pharmacology and Toxicology, Medical College of Virginia of Virginia Commonwealth University, Richmond, Virginia, USA.

The Journal of Pharmacology and Experimental Therapeutics
|September 19, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The potential effect of α7 nicotinic receptors modulation on palatable food-induced dependence-like behaviors.

Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society·2026
Same author

Peripheral Neuropathy After Chronic Alcohol Exposure in Mice: Impact of sex, total intake and duration and alcohol metabolism.

bioRxiv : the preprint server for biology·2025
Same author

Activation of α7 nicotinic receptors attenuated hyperalgesia and anxiety induced by palatable obesogenic diet withdrawal.

Journal of pharmacological sciences·2024
Same author

The potential effect of α7 nicotinic receptors modulation on palatable food-induced dependence-like behaviors.

Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society·2024
Same author

Kappa opioid receptors mediate an initial aversive component of paclitaxel-induced neuropathy.

Psychopharmacology·2020
Same author

Impact of modulation of the α7 nicotinic acetylcholine receptor on nicotine reward in the mouse conditioned place preference test.

Psychopharmacology·2019

Bupropion non-competitively blocks neuronal nicotinic acetylcholine receptors (nAChRs), explaining its effectiveness in treating nicotine dependence by inhibiting nicotine

Area of Science:

  • Neuroscience
  • Pharmacology
  • Addiction Research

Background:

  • Neuronal nicotinic acetylcholine receptors (nAChRs) are crucial for synaptic activity in the central and peripheral nervous systems.
  • Bupropion is an antidepressant also used for nicotine dependence treatment.
  • Understanding bupropion's interaction with nAChRs is key to its therapeutic effects.

Purpose of the Study:

  • To investigate the acute interaction between bupropion, nicotine, and nAChRs.
  • To determine the selectivity of bupropion for different nAChR subtypes.
  • To elucidate the mechanism of bupropion's blockade of nAChRs.

Main Methods:

  • In vivo and in vitro assays were employed to assess bupropion's effects on nicotine-induced responses.
  • Functional blockade assays were performed on specific nAChR subtypes (α3β2, α4β2, α7).

Related Experiment Videos

  • Radioligand binding assays were used to evaluate bupropion's interaction with nicotine binding sites.

    • Main Results:

    • Bupropion effectively blocked nicotine's antinociceptive, motor, hypothermic, and convulsive effects.
    • Bupropion demonstrated selectivity, being more potent in blocking α3β2 and α4β2 nAChRs than α7 nAChRs.
    • The blockade was noncompetitive and voltage-independent, suggesting it's not an open channel mechanism.

    Conclusions:

    • Bupropion's functional blockade of specific neuronal nAChRs, particularly α3β2 and α4β2 subtypes, contributes to its efficacy in nicotine dependence treatment.
    • The noncompetitive and voltage-independent nature of the blockade provides insight into its mechanism of action.
    • These findings support the therapeutic potential of targeting neuronal nAChRs for smoking cessation.